HIV Resistance Testing: Combining Genotypic and Phenotypic Approaches
Author Information
Author(s): Jan Fehr, Tracy R. Glass, Séverine Louvel, François Hamy, Hans H. Hirsch, Viktor von Wyl, Jürg Böni, Sabine Yerly, Philippe Bürgisser, Matthias Cavassini, Christoph A. Fux, Bernard Hirschel, Pietro Vernazza, Gladys Martinetti, Enos Bernasconi, Huldrych F. Günthard, Manuel Battegay, Heiner C. Bucher, Thomas Klimkait
Primary Institution: Swiss HIV Cohort Study
Hypothesis
Does adding replicative phenotypic resistance testing (rPRT) to genotypic resistance testing (GRT) improve virological response in heavily pre-treated HIV-infected patients?
Conclusion
Adding rPRT to GRT improves treatment success rates in heavily pre-treated HIV patients.
Supporting Evidence
- Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT.
- In patients with more than 2 previous failures, the odds ratio for virological response of GRT+rPRT compared to GRT was 1.45.
- Multivariate analyses indicated a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68).
Takeaway
This study found that using two types of tests to check how HIV responds to drugs can help doctors choose better treatments for patients who have already tried many options.
Methodology
Patients were followed in the Swiss HIV Cohort Study, and their virological success was assessed after switching antiretroviral therapy based on resistance testing results.
Potential Biases
Centre bias due to varying preferences for resistance testing among different clinical centres.
Limitations
The choice of resistance testing was largely centre-dependent, which may introduce bias.
Participant Demographics
Median age was 41 years, 69.4% were men, and 30.2% were drug naïve.
Statistical Information
P-Value
0.05
Confidence Interval
95% CI 1.00-2.09
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website